Sunnybrook Health Sciences Centre
Hospital
Location:
Toronto,
Canada (CA)
ISNI: 0000000097431587
ROR: https://ror.org/03wefcv03
Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018)
Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al.
Conference contribution
Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma: Final results from the global, single-arm, phase ii team trial (2017)
Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, et al.
Journal article
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4 (2017)
Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, et al.
Journal article
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2017)
Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, et al.
Journal article
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes (2017)
Clase CM, Barzilay J, Gao P, Smyth A, Schmieder R, Tobe S, Teo KK, et al.
Journal article
Risk Prediction for Early CKD in Type 2 Diabetes (2015)
Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, Teo KK, et al.
Journal article
Evaluation of current algorithms for segmentation of scar tissue from late Gadolinium enhancement cardiovascular magnetic resonance of the left atrium: An open-access grand challenge (2013)
Karim R, Housden RJ, Balasubramaniam M, Chen Z, Perry D, Uddin A, Al-Beyatti Y, et al.
Journal article